|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.310 USD | -2.96% |
|
-1.50% | -28.02% |
| 07-23 | Alzamend Neuro, Inc. Reports Earnings Results for the Full Year Ended April 30, 2026 | CI |
| 07-22 | Alzamend Neuro, Inc. Auditor Raises 'Going Concern' Doubt | CI |
Company Valuation: Alzamend Neuro, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: April | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 94.88 | 53.05 | 4.882 | 4.362 | 4.337 | 6.277 |
| Change | - | -44.08% | -90.8% | -10.66% | -0.56% | 44.72% |
| Enterprise Value (EV) | 94.88 | 53.05 | 4.882 | 4.362 | 4.337 | 6.277 |
| Change | - | -44.08% | -90.8% | -10.66% | -0.56% | 44.72% |
| P/E | -7.29x | -3.65x | -0.48x | -0.52x | -0.43x | -0.5x |
| PBR | 7.3x | - | -1.85x | - | 6.62x | -0.51x |
| PEG | - | -0.51x | 0x | 0x | 0x | 0.44x |
| Capitalization / Revenue | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - |
| EV / EBITDA | -0x | -0x | -0x | -0x | -0x | -0.59x |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -0.58x |
| EV / FCF | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -189 | -202.5 | -132.3 | -11.32 | -2.63 | -2.6 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | - | - | - | - | - | - |
| EBITDA 1 | -7.907 | -11.26 | -8.931 | -4.121 | -7.949 | -10.7 |
| EBIT 1 | -12.32 | -14.87 | -9.938 | -4.497 | -8.767 | -10.8 |
| Net income 1 | -12.36 | -14.88 | -9.948 | -5.105 | -8.772 | -10.8 |
| Net Debt | - | - | - | - | - | - |
| Reference price 2 | 1,377.000 | 738.855 | 63.990 | 5.940 | 1.140 | 1.310 |
| Nbr of stocks (in thousands) | 68.9 | 71.8 | 76.3 | 734 | 3,805 | 4,792 |
| Announcement Date | 19/07/22 | 27/07/23 | 30/07/24 | 22/07/25 | 22/07/26 | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.5x | - | - | - | 6.28M | |
| 32.83x | 5.9x | 17.55x | 0.98% | 48.53B | |
| -23.41x | 351.08x | -21.45x | -.--% | 39.87B | |
| 30.42x | 3.04x | 13.11x | -.--% | 38.68B | |
| 46.94x | 4.76x | 30.78x | -.--% | 35.13B | |
| 28.41x | 8.22x | 20.66x | 0.41% | 29.79B | |
| 32.82x | 5.37x | 24.39x | -.--% | 16.11B | |
| 22.67x | 1.99x | 8.61x | 1.17% | 13.61B | |
| 25.33x | 1.86x | 11.4x | -.--% | 12.62B | |
| Average | 21.72x | 47.78x | 13.13x | 0.32% | 26.04B | |
| Weighted average by Cap. | 23.42x | 63.80x | 12.18x | 0.32% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- ALZN Stock
- Valuation Alzamend Neuro, Inc.
Select your edition
All financial news and data tailored to specific country editions
